<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680378</url>
  </required_header>
  <id_info>
    <org_study_id>AT-103</org_study_id>
    <nct_id>NCT03680378</nct_id>
  </id_info>
  <brief_title>Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)</brief_title>
  <official_title>A Phase I Open-Label, Single-Centre Study to Assess the Concentration of AAI101 and Cefepime in Epithelial Lining Fluid and Plasma in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allecra</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allecra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to measure and compare the concentration of AAI101 and&#xD;
      cefepime in bronchial epithelial lining fluid (ELF) and plasma following administration of&#xD;
      cefepime/AAI101 combination in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration of cefepime and AAI101 in the lung</measure>
    <time_frame>Change from baseline to 2 hours, 4 hours, 6 hours and 8 hours post dose</time_frame>
    <description>Maximum concentration of cefepime and AAI101 in Bronchoalveolar lavage (BAL) samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of cefepime and AAI101 in plasma</measure>
    <time_frame>Change from baseline to 2 hours, 4 hours, 6 hours and 8 hours post dose</time_frame>
    <description>Maximum concentration of cefepime and AAI101 in plasma samples</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Cefepime 2 gram + AAI101 1 gram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cefepime 2 grams in combination with AAI101 1 gram intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefepime 2 gram</intervention_name>
    <description>Combination of cefepime 2 gram with AAI101 1 gram</description>
    <arm_group_label>Cefepime 2 gram + AAI101 1 gram</arm_group_label>
    <other_name>AAI101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Provision of signed and dated, written informed consent prior to any study-specific&#xD;
             procedures.&#xD;
&#xD;
          2. Healthy male and female subjects aged 18 to 65 years with veins suitable for&#xD;
             cannulation or repeated venipuncture. Female patients can participate if at least 1 of&#xD;
             the following criteria are met:&#xD;
&#xD;
               -  Are of non-childbearing potential defined as&#xD;
&#xD;
               -  Permanently sterile following hysterectomy, bilateral salpingectomy, bilateral&#xD;
                  oophorectomy or confirmed tubal occlusion (not tubal ligation);&#xD;
&#xD;
               -  Postmenopausal, as defined as at least 1 year post-cessation of menses (without&#xD;
                  an alternative medical cause), and per documentation provided by a medical&#xD;
                  professional;&#xD;
&#xD;
               -  Postmenopausal status will be confirmed with a screening serum follicle&#xD;
                  stimulating hormone (FSH) level greater than 40 milli-international units per&#xD;
                  milliliter (mlU/mL).&#xD;
&#xD;
               -  Patient has a negative urine and/or serum pregnancy test (serum Î²-human chorionic&#xD;
                  gonadotropin) within 1 day prior to study entry, and agrees to use highly&#xD;
                  effective contraception methods during treatment and for at least 7 days after&#xD;
                  the last dose of i.v. study therapy;&#xD;
&#xD;
          3. Have a body mass index (BMI) between 18 and 32 kg/m2.&#xD;
&#xD;
          4. As judged by the Investigator, all the subjects must be able to understand and be&#xD;
             willing to comply with study procedures, restrictions and requirements.&#xD;
&#xD;
        4.2 Exclusion criteria&#xD;
&#xD;
        Subjects should not enter the study if any of the following exclusion criteria are&#xD;
        fulfilled:&#xD;
&#xD;
          1. Male subjects who do not agree to follow contraception restrictions.&#xD;
&#xD;
          2. Female subjects who are pregnant or currently lactating&#xD;
&#xD;
          3. Female subjects who are of child bearing potential who do not agree to follow&#xD;
             contraception restrictions as detailed in section 5.1.10.&#xD;
&#xD;
          4. Donated blood in the 3 months prior to screening, plasma in the 7 days prior to&#xD;
             screening, platelets in the 6 weeks prior to screening&#xD;
&#xD;
          5. Consume more than 28 units of alcohol per week if male, or 21 units of alcohol per&#xD;
             week if female or any significant history of alcohol / substance misuse as determined&#xD;
             by the investigator&#xD;
&#xD;
          6. Unwilling to abstain from vigorous exercise for 48 hours prior to any study visit&#xD;
&#xD;
          7. Unwilling to abstain from alcohol for 48 hours prior to any study visit&#xD;
&#xD;
          8. Used cigarettes or vapor e-cigarettes, cigars or other nicotine-containing products&#xD;
             (with the exception of nicotine replacement products not covered above) within 3&#xD;
             months before bronchoscopy or have a smoking history greater than 10 pack years.&#xD;
&#xD;
          9. Received any medication, including St John's Wort, known to chronically alter drug&#xD;
             absorption or elimination within 30 days prior to first dose administration unless in&#xD;
             the opinion of the investigator it will not interfere with study procedures or&#xD;
             compromise safety&#xD;
&#xD;
         10. Received any prescribed systemic or topical medication within 14 days prior to the&#xD;
             first dose administration (with the exception of the oral contraceptive pill)&#xD;
&#xD;
         11. Received any non-prescribed systemic or topical medication, herbal remedy or vitamin /&#xD;
             mineral supplementation within 14 days prior to the first dose administration (with&#xD;
             the exception of paracetamol).&#xD;
&#xD;
         12. Subjects who have any abnormality of vital signs prior to the first dose&#xD;
             administration that, in the opinion of the investigator, would increase the risk of&#xD;
             participating in the study&#xD;
&#xD;
         13. Subjects who have any clinically significant abnormal physical examination finding&#xD;
&#xD;
         14. Subjects who have any clinically significant 12 lead ECG abnormality that, in the&#xD;
             opinion of the investigator, would increase the risk of participating in the study&#xD;
&#xD;
         15. Subjects who have, or have any history of, any clinically significant cardiovascular,&#xD;
             respiratory, gastrointestinal, neurological, psychiatric, metabolic, endocrine, renal,&#xD;
             hepatic, haematological or other major disorder as determined by the investigator&#xD;
&#xD;
         16. Subjects who have any significant condition that may preclude nasal or oral intubation&#xD;
             with a bronchoscope as determined by the investigator&#xD;
&#xD;
         17. Subjects who have any clinically significant allergy or allergic condition as&#xD;
             determined by the investigator (with the exception of non-active hay fever)&#xD;
&#xD;
         18. Subjects who have had previous adverse reactions to benzodiazepines or anaesthetic&#xD;
             agents (lidocaine or xylocaine) including reversal agents such as flumazenil&#xD;
&#xD;
         19. Subjects who have any clinically significant abnormal laboratory safety results as&#xD;
             determined by the investigator with specific exclusions of any aspartate&#xD;
             aminotransferase (AST) or alanine aminotransferase (ALT)upper limit of normal greater&#xD;
             than or equal to 1.5 times upper limit of normal (ULN) at screening or day -1; total&#xD;
             bilirubin &gt; ULN (Gilbert's syndrome is acceptable), haemoglobin &lt;12.0 g/dL or&#xD;
             prothrombin time &gt; 13 seconds (one repeat assessment is acceptable at screening)&#xD;
&#xD;
         20. Subjects who have hepatitis B or C or are carriers of HBsAg or are carriers of&#xD;
             hepatitis C virus (HCV= Ab or are positive for HIV 1/2 antibodies.&#xD;
&#xD;
         21. Subjects who have a positive alcohol breath test or a positive urine drug screen ( a&#xD;
             repeat assessment is acceptable)&#xD;
&#xD;
         22. Subjects who are still participating in another clinical study or who have&#xD;
             participated in a clinical study involving administration of an investigational&#xD;
             product in the 3 months (or 5 half-lives, whichever is longer) prior to first dose&#xD;
             administration&#xD;
&#xD;
         23. Subjects who, in the opinion of the investigator, should not participate in this study&#xD;
             For procedures for withdrawal of incorrectly enrolled subjects, see Section 5.3.&#xD;
             Subjects who drop out will be replaced.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Liverpool</name>
      <address>
        <city>Liverpool</city>
        <zip>L69 3GL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bronchial epithelial lining fluid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefepime</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

